David Molinero

Medical Flowers Developments (MFD) is pioneering the next generation of pharmaceutical-grade solutions with cannabinoids. Our mission is to transform cannabis extracts into regulated, clinical-ready medicines and devices, enabling partners to accelerate development, de-risk trials, and bring innovation to patients. Our flagship innovation is the first cannabinoid chewing gum designed to comply with the European Pharmacopoeia (Ph. Eur. 2.9.25 dissolution test). This monodose, full-spectrum, controlled-release medical device ensures pharmaceutical precision, patient safety, and superior compliance—making it the ideal dosage form for clinical trials with THC, CBD, or full-spectrum APIs. Beyond the device, MFD offers CDMO services tailored to cannabinoids: Formulation development of complex oral and mucosal delivery systems., Analytical validation, stability testing, and regulatory dossier support., GMP manufacturing of pilot and clinical batches. Our work is strengthened by collaborations with leading partners such as Cafosa Gum (RB Group), Phytoplant Research, and the University of Barcelona, ensuring industrial scalability, high-quality APIs, and regulatory compliance across Europe. Looking forward, MFD is building an AI-driven platform to match cannabis chemotypes with patient-specific needs, creating a scalable pathway towards personalized cannabinoid therapies. We are actively seeking B2B collaborators—pharmaceutical companies, biotech innovators, CROs, and research organizations—interested in: Partnering in clinical trials using our chewing gum medical device., Outsourcing formulation and GMP development through our CDMO model., Exploring licensing opportunities for innovative, cannabinoid-based medicines. With a regulated, scalable, and clinically validated approach, and with strong industrial and academic alliances, MFD is positioned to become a European leader in pharmaceutical innovation with cannabinoids